Compare HCA Health Inc (HCA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? HCA Health Inc trades at $475.56 (market cap $101.85B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.52 (market cap $977.37M). The key difference: HCA Health Inc is far larger — about 104.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and HCA Health Inc pays a 0.66% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HCA | MRVI | |
|---|---|---|
Market Cap | $101.85B | $977.37M |
Volume | 1,081,388 | 2,742,564 |
Sector | Health | Health |
52-Week High | $545.13 | $9.00 |
52-Week Low | $361.32 | $2.83 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $152.39B | $1.08B |
Dividend Yield | 0.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $460.75, up 0.47% today, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $7.59 exceeding expectations. Revenue grew to $75.60 billion in 2025, and net income reached $6.78 billion. Analyst consensus is bullish, with a $461.12 price target. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations.
Outlook remains positive due to solid demand and cost controls, but risks include regulatory scrutiny and debt levels. The stock offers growth potential from operational efficiency, though investors should monitor legal developments and payer-mix pressures. Valuation metrics like a P/E of 15.45 suggest reasonable pricing relative to earnings.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
